U.S. Stock Market Fluctuation: Syndax Plunges on October 13 Due to IPF Failure, Termination of Development, and Target Price Downgrade

Syndax October 13 Drop Analysis

Keywords: IPF failure, termination of development, target price reduction

1. On October 12, Syndax announced that the phase II IPFMAXPIRe trial of axatilimab for idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of annual decline in forced vital capacity, and decided to stop further development of this indication, which reduces the potential indications and revenue expansion for the drug.

2. On October 13, Bank of America Securities maintained a "Buy" rating but lowered Syndax's target price from $26 to $23, reflecting a valuation adjustment after the failure of the IPF trial.

(Disclaimer: This content is a summary collected from publicly available information by AI technology and is for reference only. It does not constitute investment advice.)